甘精胰岛素联合格列美脲治疗2型糖尿病80例

目的 探讨甘精胰岛素联合格列美脲治疗2型糖尿病的疗效和安全性.方法 选择医院2008年10月至2011年9月收治的80例2型糖尿病患者空腹血糖(FBG)不低于10 mmol/L],给予睡前皮下注射甘精胰岛素联合口服格列美脲治疗12周,根据FBG水平调整胰岛素用量,治疗目标为5.5 mmol/L0.05).结论 甘精胰岛素联合格列美脲治疗2型糖尿病的疗效好,低血糖发生率低,安全性好,是治疗2型糖尿病的理想方案.

Insulin Glargine Combined Glimepiride for Treating 80 Cases of Type 2 Diabetes Mellitus

Objective To explore the efficacy and safety of insulin glargine combined glimepiride in the treatment of type 11 diabetes mellitus （T2DM）. Methods Eighty cases of T2DM with fasting blood glucose （FBG）≥ 10 mmol/L in our hospital from October 2008 to September 2011 were treated with insulin glargine by subcutaneous injection before going to bed and oral glimepiride for 12 weeks. The dosage of insulin was adjusted according to FBG levels, the goals of treatment was 5.5 mmol/L〈 FBG 〈 7 mmol/L. The changes of FBG, postprandial 2 hFBG, glycated hemoglobin （HbA1c）, C-peptide, hypoglycemia and body mass index （BMI） before and after treatment were observed. Results Compared with before treatment, FBG, postprandial 2hFBG and HbAlc were significantly decreased after treatment （P 〈 0. 05）, and C- peptide level was significantly improved（P 〈 0.05）. 5 cases had hypoglycemia with the incidence rate of 6.25%, which was significantly lower than that before treatment （P 〈 0.05）. BMI had no significant change （P 〉 0. 05）. Conclusion Insulin glargine combined glimepiride is effective for treating T2DM with the low rate of hypoglycemia and good safety, which is the ideal treatment scheme of T2DM.